|
Fanconi Anemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
It is the first report of a mutation in the FANCF gene in Iranian patients with Fanconi anemia.
|
31288759 |
2019 |
|
Fanconi Anemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Many had mutations in Fanconi anemia complex genes [BRCA2 (3 participants), FANCF, FANCM].
|
28687971 |
2018 |
|
Fanconi Anemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Currently, information on the phenotypic findings of patients with Fanconi anemia from biallelic mutations in FANCF is limited.
|
27714961 |
2017 |
|
Fanconi Anemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
The Fanconi anemia (FA)‑associated proteins FANCF and FANCD2 are important components of the FA pathway of DNA crosslink repair.
|
25647473 |
2015 |
|
Fanconi Anemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Clinical aspects of Fanconi anemia individuals with the same mutation of FANCF identified by next generation sequencing.
|
26033879 |
2015 |
|
Fanconi Anemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
We found that silencing of FANCF inactivated the FA/BRCA pathway by decreasing the monoubiquitination and focus formation of FANCD2 and reduced the function of the FA/BRCA pathway, resulting in the inhibition of cell proliferation, increased cell apoptosis and DNA damage in OVCAR3 cells.
|
23440494 |
2013 |
|
Fanconi Anemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Six small molecules, including bortezomib (proteasome inhibitor), CA-074-Me (cathepsin B inhibitor) and 17-AAG (HSP90 inhibitor), synergized with cisplatin specifically in FA-proficient ovarian cancer cells (2008 + FANCF), but not in FA-deficient isogenic cells (2008).
|
22537224 |
2012 |
|
Fanconi Anemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
FANCF protein is a component of the FA core complex.
|
19813073 |
2011 |
|
Fanconi Anemia
|
0.500 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
How the fanconi anemia pathway guards the genome.
|
19686080 |
2009 |
|
Fanconi Anemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
MM1 interacts with the FA core complex by binding to FANCF, whereas MM2 interacts with RM1 and topoisomerase IIIalpha, components of the BS complex.
|
20064461 |
2009 |
|
Fanconi Anemia
|
0.500 |
PosttranslationalModification
|
disease |
BEFREE |
However, only a single leukaemic case with methylation of one of the FA-BRCA genes has been described to date, i.e. methylation of FANCF in cell line CHRF-288.
|
18607065 |
2008 |
|
Fanconi Anemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
These low proportions suggest that in contrast to other types of tumors silencing of FANCF is a rare event in bladder cancer and that an intact FA/BRCA pathway might be advantageous for tumor progression.
|
18000367 |
2007 |
|
Fanconi Anemia
|
0.500 |
PosttranslationalModification
|
disease |
BEFREE |
Inactivation of the Fanconi Anemia (FANC-BRCA) pathway via promoter methylation of the FANCF gene has been proposed to be responsible for variation in cisplatinum (CDDP) sensitivity seen in ovarian and HNSCCs.
|
16466850 |
2007 |
|
Fanconi Anemia
|
0.500 |
PosttranslationalModification
|
disease |
BEFREE |
Affected cellular pathways may be modulated in sporadic malignancies and silencing of FANCF through methylation has been shown to cause somatic disruption of the FA pathway.
|
16803569 |
2006 |
|
Fanconi Anemia
|
0.500 |
PosttranslationalModification
|
disease |
BEFREE |
Methylation-induced inactivation of FANCF plays an important role in the occurrence of ovarian cancers via disrupting the FA-BRCA pathway.
|
16418574 |
2006 |
|
Fanconi Anemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Three-hybrid experiments also demonstrated the ability of FANCE to mediate the interaction between FA core complex components FANCC and FANCF, indicating an additional role for FANCE in complex assembly.
|
16127171 |
2005 |
|
Fanconi Anemia
|
0.500 |
PosttranslationalModification
|
disease |
BEFREE |
Promoter hypermethylation of FANCF: disruption of Fanconi Anemia-BRCA pathway in cervical cancer.
|
15126331 |
2004 |
|
Fanconi Anemia
|
0.500 |
GeneticVariation
|
disease |
CLINVAR |
The Fanconi anemia gene product FANCF is a flexible adaptor protein.
|
15262960 |
2004 |
|
Fanconi Anemia
|
0.500 |
PosttranslationalModification
|
disease |
BEFREE |
A new model of ovarian cancer tumor progression implicates aberrant FANCF promoter methylation that is associated with gene silencing and disruption of the Fanconi-anemia-BRCA pathway.
|
12781358 |
2003 |
|
Fanconi Anemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Previous work has shown that the AML cell line CHRF-288, derived from a sporadic AML-M7 patient, does not express FANCF protein and exhibits a cellular FA phenotype.
|
14617007 |
2003 |
|
Fanconi Anemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Fanconi anaemia (FA) comprises a group of autosomal recessive disorders resulting from mutations in one of eight genes (FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF and FANCG).
|
12001267 |
2002 |
|
Fanconi Anemia
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
FANCF protein expression is normal in cells derived from all FA complementation groups except FA-F and does not vary during cell cycle progression.
|
11750104 |
2001 |
|
Fanconi Anemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
The recent cloning of the FANCF and FANCE genes has allowed us to investigate the interaction of the proteins encoded by five of the seven complementation groups of FA.
|
11157805 |
2001 |
|
Fanconi Anemia
|
0.500 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
The Fanconi anaemia gene FANCF encodes a novel protein with homology to ROM.
|
10615118 |
2000 |
|
Fanconi Anemia
|
0.500 |
CausalMutation
|
disease |
CLINVAR |
|
|
|